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Introduction 
Bilirubin is the catabolic end-product of heme metabolism 
which originates from the degradation of erythrocyte 
hemoglobin in the reticuloendothelial system, inefficient 
erythropoiesis in bone marrow, and degradation of other 
heme proteins (1). The level of serum total bilirubin 
is widely used to identify hepatobiliary function and 
hemolytic diseases (2). The etiology of hyperbilirubinemia 
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is multifactorial and includes advanced liver disease, 
sepsis, and bleeding (3,4). Thus, clearly identifying the 
cause of persistent hyperbilirubinemia is essential to guide 
subsequent treatment (3,4).
Lung transplantation has become an established 
treatment option for patients with end-stage lung 
disease,  and the number of lung transplantations 
has steadily increased (5). As lung transplantation 
has become more widespread, several complications 
after lung transplantation have been reported (6,7). 
Hyperbilirubinemia after organ transplantation has been 
reported (8-10), and we have encountered rare causes 
of hyperbilirubinemia after lung transplantation at our 
center. Previous research reported that hyperbilirubinemia 
is common among patients with pulmonary hypertension 
and that these patients have greater mortality during 
heart–lung transplantation (11). However, most cases of 
hyperbilirubinemia were associated with transplantation of 
organs other than the lungs.
In this study, we investigated the cause, frequency, 
prognosis and clinical characteristics of unexpected and rare 
causes of hyperbilirubinemia after lung transplantation. 
Methods
Study design 
This study was a retrospective case series of patients 
who were developed hyperbilirubinemia after lung 
transplantation. Between December 22, 2010 and January 
01, 2016, 116 patients underwent lung transplantation at 
Severance Hospital and Gangnam Severance Hospital in 
South Korea. 
All donor lungs were transplanted from patients after 
brain death and preserved using low-potassium dextran 
solution (Perfadex®; Duraent Biologicals, Hyderabad, 
India). During lung transplantation surgery, extracorporeal 
membrane oxygenation (ECMO) or cardiopulmonary 
bypass was applied to all patients for cardiopulmonary 
support. All patients were received corticosteroids for 
immunosuppression at the time of transplantation surgery 
and maintained on triple immunosuppression therapy 
including prednisolone, tacrolimus, and mycophenolate 
mofetil (MMF) after transplantation. 
Data collection and definition
The normal range of serum total bilirubin at our center is 
between 0.4 and 1.5 mg/dL. We defined hyperbilirubinemia 
as total bilirubin level exceeding 5 mg/dL for at least 
3 days after lung transplantation. We defined common 
cause of hyperbilirubinemia that included drug toxicity, 
sepsis, biliary tract stone, bleeding and other clinically 
easily predicted causes. Patient data such as demographic, 
laboratory, mortality, medications, imaging, and other 
data were collected from the hospital’s electronic medical 
records.
Statistical analysis
Data were expressed as median plus range or interquartile 
range. Statistical analyses were performed with SPSS 
version 23 statistical software. Differences between rare 
causes of hyperbilirubinemia group and common causes 
of hyperbilirubinemia group were compared using the 
Mann Whitney U test. P<0.05 were considered statistically 
significant.
Results
A total of 116 patients received lung transplantation, 
and 33 (28.4%) lung transplant recipients developed 
hyperbilirubinemia during the study period (Table 1). 
The leading cause of lung transplantation was idiopathic 
pulmonary fibrosis (48.3%), followed by bronchiolitis 
obliterans after stem cell transplantation (12.1%) and 
interstitial lung disease related to connective tissue disease 
(10.3%). Ten patients out of 116 patients had chronic liver 
disease. Among them, four patients had mild fatty liver 
disease, four patients had well controlled chronic hepatitis 
B, one patient had alcoholic liver disease, and one had liver 
failure. The patient with liver failure patient underwent 
simultaneous lung and liver transplantation. 
Among the 33 patients with hyperbilirubinemia, 
24 patients had common causes of hyperbilirubinemia 
such as drug toxicity, biliary tract stone, sepsis, bleeding, 
and liver failure after lung transplantation with liver 
transplantation. Nine patients had unexpected, rare 
causes of hyperbilirubinemia including hemophagocytic 
lymphohistiocytosis (HLH), thrombotic microangiopathy 
(TMA), and ischemic cholangiopathy. 
The  base l ine  charac ter i s t i c s  o f  pa t ient s  w i th 
hyperbilirubinemia after lung transplantation are described 
in Table 2. The most common cause of hyperbilirubinemia 
was sepsis (N=11, 33.3%). Patients who developed 
hyperbilirubinemia had a poor prognosis, and the recovery 
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rate of hyperbilirubinemia was low (N=5, 15.2%). Causes 
of normalized hyperbilirubinemia were bleeding, drugs, 
and biliary tract stones. Four of the five patients who 
recovered from hyperbilirubinemia were still alive at 
the 180-day follow-up, and the remaining 29 patients 
with hyperbilirubinemia expired within 180 days after 
lung transplantation. Sepsis was the leading cause of 
death (N=16), followed by liver failure due to ischemic 
cholangiopathy (N=4), TMA (N=3), HLH (N=2), bleeding 
(N=2) and sudden cardiac arrest (N=2). Median age, male 
sex, and median body mass index did not differ according 
to cause of hyperbilirubinemia. However, the median onset 
time of hyperbilirubinemia after lung transplantation in 
cases with rare causes was relatively late (88 vs. 6.5 days, 
P<0.001) compared to cases with common causes. Three 
patients among those with hyperbilirubinemia had liver 
disease and no distinct types were noted.
The demographic characteristics of the 9 patients with 
rare causes of hyperbilirubinemia are presented in Table 3. 
Two patients had HLH, and both were intubated and 
mechanically ventilated before transplantation. Patients 
underwent imaging using abdominal ultrasonography, 
abdominal computed tomography (CT), or magnetic 
resonance cholangiopancreatography (MRCP) after 
developing hyperbilirubinemia. However, imaging studies 
did not reveal abnormalities in the biliary tract or liver 
parenchyma. Patients had hyperbilirubinemia with ongoing 
pancytopenia of unknown origin. Various laboratory 
tests were performed (Table S1); however, the reason for 
pancytopenia was not determined. Finally, bone marrow 
aspiration and biopsy were conducted. HLH was diagnosed 
based on the clinical findings, laboratory findings, and bone 
marrow biopsy results. 
Three patients were diagnosed with TMA. None were 
intubated or mechanically ventilated before transplantation. 
All underwent abdominal imaging with ultrasonography 
and CT upon detection of hyperbilirubinemia. However, 
imaging did not reveal abnormalities in the biliary 
tract or liver parenchyma. We conducted a peripheral 
blood smear due to thrombocytopenia and discovered 
schistocytes. Additionally, the haptoglobulin level was 
low, and the reticulocyte level was high, which suggested 
hemolytic anemia. One patient underwent a bone marrow 
biopsy, which showed nonspecific findings. To evaluate 
microangiopathic hemolytic anemia (MAHA), ADAMTS13 
activity was evaluated in two patients and found to be 
normal or only mildly decreased (Table S1). We supposed 
that hyperbilirubinemia was caused by TMA, which might 
be related to the use of tacrolimus. 
Four  pa t i en t s  were  d i agnosed  w i th  i s chemic 
cholangiopathy. Three were intubated and mechanically 
ventilated before transplantation. Patients underwent 
abdominal imaging with several modalities including 
ultrasonography, CT, and MRCP. Imaging studies 
revealed features of ischemic cholangiopathy and no 
obstruction of the biliary tract (Figure 1). Case 6 was 
diagnosed after undergoing endoscopic retrograde 
Table 1 Characteristics of all patients who underwent lung 
transplantation surgery
Variables 
Total patients 
(N=116) 
Age, year 53.5 [16–75]
Male gender 64 (55.2) 
BMI, kg/m2, median (IQR) 19.7 (17.6–23.2)
LTx type, bilateral 106 (91.4)
Ventilator before LTx 40 (34.5)
ECMO before LTx 23 (19.8)
Ever smoker 49 (42.2)
90 days survivor 92 (79.3)
180 days survivor 73 (62.9) 
Patients with hyperbilirubinemia 33 (28.4)
Primary cause of lung transplantation
COPD/emphysema 2 (1.7)
IPF 56 (48.3)
Idiopathic pulmonary arterial hypertension 2 (1.7)
Pulmonary fibrosis, other: NSIP, AIP 9 (7.8)
Bronchiectasis 8 (6.9)
Bronchiolitis obliterans syndrome after SCT 14 (12.1)
Interstitial lung disease related with 
connective tissue disease
12 (10.3)
LAM 9 (7.8)
Others* 4 (3.4)
Data are shown as number (%) or median (range). *, chronic 
hypersensitivity pneumonitis, destroyed lung, langerhans cell 
histiocytosis. BMI, body mass index; IQR, interquartile range; 
LTx, lung transplantation; ECMO, extracorporeal membrane 
oxygenation; COPD, chronic obstructive pulmonary disease; 
IPF, idiopathic pulmonary fibrosis; NSIP, non-specific interstitial 
pneumonia; AIP, acute interstitial pneumonia; SCT, stem cell 
transplantation; LAM, lymphangioleiomyomatosis.
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Table 2 Baseline characteristic of hyperbilirubinemia patients after lung transplantation 
Variables Total, N=33 Rare causes, N=9 Common causes, N=24 P
Age, year 60 [17–73] 62 [27–73] 58 [17–72] 0.437
Male gender 24 (72.7) 5 (55.6) 19 (79.2) 0.212
BMI, kg/m2, median (IQR) 21.3 (19.2–23.5) 19.9 (17.3–22.7) 21.4 (19.4–24.7) 0.193
LTx type, bilateral 31 (93.9) 8 (88.9) 23 (95.8) 0.477
Interval between onset of hyperbilirubinemia and LTx, day 21 [0–143] 88 [48–143] 6.5 [0–137] <0.001*
Peak bilirubin level 18 (5.9–49.6) 18 (12.7–31.2) 19.2 (12.4–27.8) 0.953
Normalization of bilirubin 5 (15.2) 0 (0) 5 (20.8) 0.290
Liver disease before LTx† 3 (9.1) 2 (22.2) 1 (4.2) 0.174
DM 6 (18.2) 2 (22.2) 4 (16.7) 1.000
Cardiovascular disease 7 (21.2) 3 (33.3) 4 (16.7) 0.358
Ventilator before LTx 17 (51.5) 5 (55.6) 12 (50.0) 1.000
ECMO before LTx 11 (33.3) 2 (22.2) 9 (37.5) 0.681
Ever smoker 17 (51.5) 4 (44.4) 13 (54.2) 0.708
90 days survivor 18 (54.5) 8 (88.9) 10 (41.7) 0.021*
180 days survivor 4 (12.1) 0 (0) 4 (16.7) 0.555
Primary cause of LTx 0.299
IPF 23 (69.7) 6 (66.7) 17 (70.8)
Pulmonary fibrosis, other 4 (12.1) 2 (22.2) 2 (8.3)
Bronchiolitis obliterans syndrome after SCT 2 (6.1) 0 (0) 2 (8.3)
Idiopathic pulmonary arterial hypertension 1 (3.0) 1 (11.1) 0 (0)
Interstitial lung disease related with connective tissue disease 3 (9.1) 0 (0) 3 (12.5)
Cause of hyperbilirubinemia –
Ischemic cholangiopathy 4 (12.1) 4 (44.4) –
HLH 2 (6.1) 2 (22.2) –
TMA 3 (9.1) 3 (33.3) –
IHD stone, GB stone 3 (9.1) – 3 (12.5)
Drug 3 (9.1) – 3 (12.5)
Bleeding 2 (6.1) – 2 (8.3)
Sepsis 11 (33.3) – 11 (45.8)
Others‡ 5 (15.2) – 5 (20.8)
Data are shown as number (%) or median (range). †, Alcoholic liver cirrhosis, Chronic Hepatitis; ‡, liver transplantation, shock, unknown; 
*, significant at P<0.05. IQR, interquartile range; BMI, body mass index; LTx, lung transplantation; DM, diabetic mellitus; ECMO, 
extracorporeal membrane oxygenation; IPF, idiopathic pulmonary fibrosis; SCT, stem cell transplantation; HLH, hemophagocytic 
lymphohistiocytosis; TMA, thrombotic microangiopathy; IHD, intrahepatic duct; GB, gallbladder.
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cholangiopancreatography (ERCP), liver biopsy and 
imaging. The ERCP revealed small filling defects and 
dilatation of both intrahepatic ducts. Liver biopsy in case 6 
revealed intrahepatic cholestasis and portal widening with 
acute inflammatory cell infiltration. The result of the liver 
biopsy in case 7 revealed the development of cholestatic 
hepatitis. Cases 8 and 9 were diagnosed without liver 
biopsy because these patients had very similar findings with 
regard to laboratory studies, imaging studies, and clinical 
characteristics as cases 6 and 7. 
The time interval  between transplantation and 
hyperbilirubinemia was approximately 2 months in patients 
with HLH and ischemic cholangiopathy, and approximately 
4 months in patients with TMA (Table 3).  
The two patients diagnosed with HLH were treated 
with etoposide plus steroid or steroid alone, and the three 
patients who developed TMA had their treatment changed 
to basiliximab from tacrolimus with plasmapheresis. 
The four pat ients  with i schemic cholangiopathy 
received supportive treatment including endoscopic 
retrograde biliary drainage or percutaneous transhepatic 
bi l iary drainage.  However,  al l  nine patients with 
hyperbilirubinemia of rare causes died due to progression of 
HLH, TMA or ischemic cholangiopathy during long term 
intensive care unit treatment (Table 3). 
Discussion 
In the present study, we found that hyperbilirubinemia 
occurred at a rate of 28.4% (33/116) in patients who 
received lung transplants at our institution, and the rate of 
hyperbilirubinemia due to rare causes such as HLH, TMA, 
and ischemic cholangiopathy was 7.8% (9/116) during the 
study period. 
We fur ther  found  tha t  most  causes  o f  severe 
hyperbilirubinemia were not hepatic but systemic 
problems and associated with poor prognosis. In our 
institution, the most common cause of 1-year mortality 
was infection (58.3%), followed by cardiac arrest (12.5%) 
and TMA (12.5%). Some patients died due to HLH, 
ischemic cholangiopathy, or bleeding. Except sudden 
cardiac arrest, most causes of mortality could induce 
hyperbilirubinemia (12). 
HLH is a potentially life-threatening hyperinflammatory 
syndrome that is divided into primary and secondary 
(or acquired) HLH. Our cases were secondary HLH. 
Acquired HLH without a genetic cause develops due 
to infections, autoimmune diseases, malignancies or T
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other stimuli. A number of clinical symptoms can be 
observed in patients with HLH including persistent fever, 
multiple organ involvement, and laboratory abnormalities 
including cytopenia, increased serum ferritin level, 
abnormal liver function tests (aspartate transaminase, 
alanine aminotransaminase, gamma-glutamyl transferase, 
bilirubin, lactate dehydrogenase), and abnormal coagulation 
parameters. High-dose corticosteroid, etoposide, and 
cyclosporine have been suggested as treatments for primary 
HLH. However, a treatment regimen for acquired HLH 
does not yet exist, and the prognosis of acquired HLH 
is poorer than that of primary HLH (13). The poor 
prognosis of our cases with acquired HLH after lung 
transplantation is consistent with previous reports (14,15). 
In patients who undergo lung transplantation, the immune 
system is altered by the use of immunosuppressive drugs. 
Therefore, these patients are at high risk of opportunistic 
infection and sepsis. We speculate that infection and severe 
inflammation in our cases were associated with HLH after 
lung transplantation. Although the pathogenesis of acquired 
HLH remains unclear, several studies suggest that HLH 
is associated with inflammation (16-18). Furthermore, in 
many patients, HLH may be accompanied by hepatitis, 
because HLH induces excessive inflammation and tissue 
destruction (19). Therefore, HLH should be considered in 
the differential diagnosis of hyperbilirubinemia after lung 
transplantation when the origin of hyperbilirubinemia is 
unknown. 
TMA induced by various causes is characterized by 
MAHA, thrombocytopenia, microvascular thrombosis, and 
organ injury (20). Several drugs associated with TMA have 
been reported (20,21). These drugs mediated TMA through 
immune or toxic dose-duration-related reactions (20). 
In an analysis of 387 articles, Al-Nouri et al. reported that 
22 drugs had definite evidence of association with TMA, 
three of which (quinine, cyclosporine, and tacrolimus) 
accounted for approximately 58 percent of drug-induced 
TMA cases (21). We speculate that the TMA cases in our 
study were associated with tacrolimus, because all patients 
developed hyperbilirubinemia after at least 3 months 
of immunosuppressive therapy, and TMA temporarily 
improved after stopping the use of tacrolimus with plasma 
exchange. Furthermore, we could not find other causes of 
TMA. ADAMTS13 activity and complement level support 
this diagnosis. MAHA, which is caused by TMA, increases 
the indirect bilirubin level by destroying red blood cells. 
Therefore, TMA should be considered in the differential 
diagnosis of hyperbilirubinemia of unknown origin after 
lung transplantation, because urgent management in 
suspected TMA is important (22). 
Ischemic cholangiopathy is induced by impaired 
blood supply, especially the peribiliary vascular plexus 
from hepatic arteries (23). Ischemic cholangiopathy 
can have various causes including liver transplantation, 
vascular injury during surgery, chemotherapy, biliary 
ischemia in hereditary hemorrhagic telangiectasia, or 
A B
Figure 1 MRI imaging of ischemic cholangiopathy patients. (A) Showed innumerable irregular small cystic lesions along the entire IHD and 
dilated IHD with multifocal stricture including the hilar portion without demonstrable mass lesion; (B) showed multifocal irregular beaded 
appearance and wall thickening of the IHD. There were not definitely visualized stones in IHD or CBD. MRI, magnetic resonance imaging; 
IHD, intrahepatic duct; CBD, common bile duct.
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secondary sclerosing cholangitis in critically ill patients 
(23,24). Patients with ischemic cholangiopathy present 
with clinical features including jaundice, pruritus, and 
dark urine. Although there are several radiological 
features of primary sclerosing cholangitis, abdominal 
ultrasonography or CT can reveal normal findings. 
Therefore, the diagnosis of ischemic cholangiopathy 
generally requires magnetic resonance imaging (MRI) or 
cholangiography (23,25). Liver transplantation is the most 
common cause of ischemic cholangiopathy (23); however, 
ischemic cholangiopathy after lung transplantation has 
not been previously reported. We speculate that our cases 
were associated with prolonged hypoxic damage due to 
ventilator care before transplantation and septic shock 
after transplantation. In view of prolonged ischemia, 
several papers have reported on the relationship between 
critical illness and ischemic cholangiopathy (24,26,27). 
Abbasi et al. reported that longer duration of ECMO and 
ECMO-related complications were associated with the 
development of cholestasis in neonates (28). In our study, 
only one of our patients with ischemic cholangiopathy had 
experienced ECMO before lung transplantation. Seventeen 
patients with hyperbilirubinemia weaned the ECMO in 
the intensive care unit (ICU) after lung transplantation. 
One out of 17 patients was diagnosed with ischemic 
cholangiopathy. There was no association between 
delayed ECMO weaning or duration of ECMO use and 
cause of hyperbilirubinemia. Therefore, the relationship 
between ECMO and ischemic cholangiopathy was 
unclear in our study. The optimal treatment of ischemic 
cholangiopathy has not yet been established (23). Despite 
efforts including endoscopic retrograde biliary drainage 
and percutaneous transhepatic biliary drainage, all our 
patients died. Taken together, ischemic cholangiopathy 
should also be considered in the differential diagnosis of 
hyperbilirubinemia when patients have been exposed to 
shock or have findings of obstructive jaundice without a 
definite obstruction on abdominal ultrasonography or CT. 
Although causes of hyperbilirubinemia can vary widely 
(3,4), only few cases of hyperbilirubinemia with rare causes 
after lung transplantation have been reported (14,15,29-31). 
Furthermore, we did not find any reports on the association 
of lung transplantation with ischemic cholangiopathy. 
Patients with rare causes of hyperbilirubinemia after lung 
transplantation had a poor prognosis; therefore, early 
evaluation and management of hyperbilirubinemia are 
essential to improving prognosis. Several imaging studies 
including abdominal ultrasonography, CT, and MRI; clinical 
manifestations; time interval between transplantation and 
hyperbilirubinemia detection; and various laboratory tests 
may be helpful for the differential diagnosis of causes of 
hyperbilirubinemia.
This study has several limitations. First, the sample size is 
relatively small. Second, this study is a retrospective analysis 
and a single-center experience. Third, we cannot rule out 
the effects of cardiopulmonary support because we used 
ECMO or cardiopulmonary bypass during all operations. 
Finally, patients who developed hyperbilirubinemia may 
have complex, multifactorial causes of hyperbilirubinemia 
and we were unable to account for all of these due to the 
retrospective nature of this study. Additional prospective 
and multicenter studies are needed to assess the incidence, 
causes, prognosis, and risk factors of hyperbilirubinemia 
after lung transplantation.
Conclusions 
Causes of hyperbilirubinemia after lung transplantation 
are varied, and the prognosis of patients with rare causes of 
hyperbilirubinemia was poor. Therefore, early evaluation 
and management of hyperbilirubinemia may be necessary if 
it develops after lung transplantation. 
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Table S1 Specific studies of each patient due to hyperbilirubinemia
Number, cause of hyperbilirubinemia Specific tests among patients 
Case 1, HLH BM study: histiocytosis with occasional hemophagocytes is noted; increased number of stromal macrophages (CD68) 
Haptoglobin: 42.99 mg/dL [30–200]
Serum ferritin: 2,495.5–4,518.2 ng/mL (23.9–336.2) 
TG level: 127 mg/dL
Soluble Interleukine-2 receptor: 8,730 U/mL
PB smear: nonspecific finding 
Case 2, HLH BM study: hemophagocytes are occasionally seen; CD68: positive in increased histiocytes; CD8: focal positive in increased cytotoxic T cells
Haptoglobin: 185.48 mg/dL [30–200]
Serum ferritin: 6,218.8 ng/mL (23.9–336.2) 
TG level: 505 mg/dL
Soluble Interleukine-2 receptor: 1,700 U/mL
PB smear: nonspecific finding 
ADAMTS 13 activity: 87% 
Case 3, TMA BM study: no evidential finding of bone marrow involvement of hematologic malignancy
EEG: abnormal awake and drowsy EEG, these features suggest moderate to severe diffuse cerebral dysfunction
Haptoglobin: <10 mg/dL [30–200] 
Reticulocyte, percent/ absolute counts: 6.46 %, 179,600/μL
PB smear: schistocyte 19–20/HPF
Case 4, TMA Haptoglobin: <10 mg/dL [30–200] 
Reticulocyte, percent/ absolute counts: 5.10 %, 147,000/μL
Serum ferritin: 5,487 ng/mL (23.9–336.2) 
PB smear: schistocyte 10/HPF
ADAMTS 13 activity and Inhibitor: 6% and 0 BU/mL 
Case 5, TMA Haptoglobin: <10 mg/dL [30–200]
Reticulocyte, percent/absolute counts: 9.93 %, 197,000/μL
PB smear: schistocyte positive
Serum ferritin: 1,621.1 ng/mL [23.9–336.2] 
ADAMTS 13 activity: 24% 
Brain MRI: no remarkable findings
Case 6, ischemic cholangiopathy MRI: innumerable irregular small cystic lesions along the entire IHD; dilated IHD with multifocal stricture including the hilar portion without 
demonstrable mass lesion
Liver biopsy: hepatocellular ballooning degeneration, microvesicular steatosis and intrahepatic cholestasis in zone 3; bile duct damage showing 
reactive change, proliferation and bile plugging; portal widening with acute inflammatory cell infiltration and periportal fibrosis; canalicular and 
intrahepatocytic cholestasis
ERCP: both IHD dilatation and small filling defects; no CHD and CBD lesion
Haptoglobin: 219.5 [30–200]
PB smear: nonspecific finding 
ANA: negative 
Anti-ds DNA antibody: negative
Anti-smooth muscle antibody: negative 
Anti-mitochondrial antibody: negative 
Case 7, ischemic cholangiopathy MRI: multifocal irregular beaded appearance of the IHD; no definitely visualized stones in IHD or CBD; irregular wall thickening and enhancement 
of both IHD; no abnormal lesion in the liver, pancreas and gall bladder
Liver biopsy: cholestatic hepatitis showing ballooning degeneration, occasional acidophilic bodies and mild portal lymphocytic infiltration
Serum ferritin: 1,745.9 ng/mL (23.9–336.2) 
PB smear: nonspecific finding 
ANA: negative 
Anti-ds DNA antibody: negative 
Anti-smooth muscle antibody: negative 
Anti-mitochondrial antibody: negative 
P-ANCA and C-ANCA: negative and negative 
Anti-LKM antibody: negative 
Case 8, ischemic cholangiopathy  CT: multifocal dilatation of IHD without definite obstructive lesion; mild GB and periportal edema
PB smear: nonspecific finding
ANA: negative 
Anti-ds DNA antibody: negative 
P-ANCA and C-ANCA: negative and negative 
Anti-GBM antibody: negative 
Case 9, ischemic cholangiopathy MRI: irregular bead-like dilatation of intrahepatic bile ducts is in both lobes of liver, more prominent on the Lt. lobe; no evidence of obstructive 
lesion is in bile duct; no significant focal lesions in liver
PB smear: non-specific finding
ANA: negative 
Anti-smooth muscle antibody: negative 
Anti-mitochondrial antibody: negative 
Anti-cyclic citrullinated peptide antibody: negative 
P-ANCA and C-ANCA: negative and negative
Anti-LKM antibody: negative 
POD, postoperative day; TMA, thrombotic microangiopathy; BM, bone marrow; TG, triglyceride; PB, peripheral blood; ADAMTS, a disintegrin and metalloproteinase with thrombospondin 
motifs; EEG, electroencephalography; MRI, Magnetic resonance imaging; ERCP, endoscopic retrograde cholangiopancreatography; IHD, intrahepatic duct; CHD, common hepatic duct; 
CBD, common bile duct; ANA, antinuclear antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; LKM, liver kidney microsomal; GBM, glomerular basement membrane.
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